Literature DB >> 813397

Screening and the detection of gonorrhea.

K K Holmes.   

Abstract

The purpose of a physician's screening for gonorrhea is the provision of comprehensive health care to patients who seek his care. Among sexually active young patients, gonorrhea is probably far more common than many other diseases a physician "screens" for during a routine physical examination. Since gonorrhea culture tests are too costly in time and money to be offered to every patient, guidelines can be used to select patients for screening who are most likely to have gonorrhea. The gonorrhea culture test should be carried out in the same spirit as a cervical cytology test, as a potential health benefit and without stigma.However, even more important than gonorrhea screening, from the standpoint of the patient, is (1) increased use of culture for diagnostic problem solving, particularly in women with dysuria, abnormal vaginal discharge, abnormal menstrual bleeding or lower abdominal pain, and (2) location and treatment of sex partners.

Entities:  

Mesh:

Year:  1975        PMID: 813397      PMCID: PMC1129912     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  4 in total

1.  Judgment under Uncertainty: Heuristics and Biases.

Authors:  A Tversky; D Kahneman
Journal:  Science       Date:  1974-09-27       Impact factor: 47.728

2.  Neonatal gonococcal infection. I. Orogastric contamination with Neisseria gonorrhoea.

Authors:  H H Handsfield; W A Hodson; K K Holmes
Journal:  JAMA       Date:  1973-08-13       Impact factor: 56.272

3.  Screening females for asymptomatic gonorrhea infection.

Authors:  A H Pedersen; P Bonin
Journal:  Northwest Med       Date:  1971-04

4.  Culture of urinary sediment for the diagnosis of gonorrhoea in women.

Authors:  T A Chapel; M Smeltzer
Journal:  Br J Vener Dis       Date:  1975-02
  4 in total
  1 in total

1.  Cost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis.

Authors:  M Genç; P A Mårdh
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.